CN1918298B - 利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法 - Google Patents

利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法 Download PDF

Info

Publication number
CN1918298B
CN1918298B CN028291794A CN02829179A CN1918298B CN 1918298 B CN1918298 B CN 1918298B CN 028291794 A CN028291794 A CN 028291794A CN 02829179 A CN02829179 A CN 02829179A CN 1918298 B CN1918298 B CN 1918298B
Authority
CN
China
Prior art keywords
arginase
hours
lane
protein
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN028291794A
Other languages
English (en)
Chinese (zh)
Other versions
CN1918298A (zh
Inventor
郑宁民
梁润松
劳伟雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Cancer Treatment International Ltd
Original Assignee
Bio Cancer Treatment International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1918298(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio Cancer Treatment International Ltd filed Critical Bio Cancer Treatment International Ltd
Publication of CN1918298A publication Critical patent/CN1918298A/zh
Application granted granted Critical
Publication of CN1918298B publication Critical patent/CN1918298B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN028291794A 2002-06-20 2002-09-09 利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法 Expired - Lifetime CN1918298B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39075702P 2002-06-20 2002-06-20
US60/390,757 2002-06-20
PCT/CN2002/000635 WO2004001048A1 (en) 2002-06-20 2002-09-09 Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008102148652A Division CN101433714A (zh) 2002-06-20 2002-09-09 利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法

Publications (2)

Publication Number Publication Date
CN1918298A CN1918298A (zh) 2007-02-21
CN1918298B true CN1918298B (zh) 2011-06-29

Family

ID=30000613

Family Applications (2)

Application Number Title Priority Date Filing Date
CN028291794A Expired - Lifetime CN1918298B (zh) 2002-06-20 2002-09-09 利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法
CNA2008102148652A Pending CN101433714A (zh) 2002-06-20 2002-09-09 利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008102148652A Pending CN101433714A (zh) 2002-06-20 2002-09-09 利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法

Country Status (12)

Country Link
US (4) US7951366B2 (https=)
EP (1) EP1517699B1 (https=)
JP (2) JP5307042B2 (https=)
CN (2) CN1918298B (https=)
AT (2) ATE385807T1 (https=)
AU (1) AU2002325782A1 (https=)
DE (2) DE60331871D1 (https=)
HK (1) HK1053577A2 (https=)
IL (1) IL165858A (https=)
MX (1) MXPA04012970A (https=)
NZ (1) NZ537774A (https=)
WO (1) WO2004001048A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745847A (zh) * 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US20090068166A1 (en) * 2006-03-17 2009-03-12 Ning Man Cheng Method and composition for protection against radiation
US20080138858A1 (en) * 2006-12-12 2008-06-12 Bio-Cancer Treatment International Ltd. Expression System for Recombinant Human Arginase I
US8815232B2 (en) * 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
CA2742497C (en) * 2008-10-31 2024-01-23 George Georgiou Compositions of engineered human arginases and methods for treating cancer
AU2010242422B2 (en) * 2009-03-26 2014-12-04 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
WO2011008495A2 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
CN103184208B (zh) 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
CN106456723B (zh) 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
JP2016117702A (ja) * 2014-12-22 2016-06-30 武輝 山田 ガン細胞の死滅法
CN105062941B (zh) * 2015-08-25 2019-03-05 江南大学 一种利用重组枯草芽孢杆菌全细胞转化生产l-鸟氨酸的方法
US20180271960A1 (en) * 2015-09-21 2018-09-27 Bio-Cancer Treatment International Ltd. Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
CN105112391B (zh) * 2015-09-22 2018-07-06 浙江道尔生物科技有限公司 一种人源精氨酸酶突变体及其制备方法和用途
GB2568000A (en) 2016-08-08 2019-05-01 Aerase Inc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
CN120661640A (zh) 2017-12-05 2025-09-19 伊梅尔迪卡制药公司 用于治疗精氨酸酶1缺乏症的方法和组合物
AU2019275733B2 (en) * 2018-05-31 2025-07-31 The Chinese University Of Hong Kong Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
WO2020081994A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
KR20220082813A (ko) 2019-08-30 2022-06-17 아이글레아 바이오테라퓨틱스, 인크. 인간 재조합 아르기나아제 1의 제조 방법 및 이의 사용
US20210162028A1 (en) * 2019-12-02 2021-06-03 The Hong Kong Polytechnic University Methods for Inducing Intermittent Fasting and Modulating Autophagy
EP4169526A1 (en) * 2021-10-21 2023-04-26 Kyon Biotech AG Arginase based cancer therapy
CN115804845B (zh) * 2022-12-02 2025-09-30 华东理工大学 精氨酸剥夺在延缓衰老与联合化疗药物治疗肿瘤中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0825260A2 (en) * 1996-08-20 1998-02-25 Smithkline Beecham Corporation Arginase II
US6261557B1 (en) * 1996-08-16 2001-07-17 Slobodan Tepic Arginine decomposing enzyme therapeutic composition
CN1324942A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶9和编码这种多肽的多核苷酸
CN1324945A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——精氨酸酶12和编码这种多肽的多核苷酸
CN1345966A (zh) * 2000-09-26 2002-04-24 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶35.42和编码这种多肽的多核苷酸
CN1345970A (zh) * 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——含精氨酸酶结构域的蛋白质9.35和编码这种多肽的多核苷酸

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5192498A (en) * 1996-12-03 1998-06-29 Kyowa Hakko Kogyo Co. Ltd. Tissue fibrosis inhibitor
WO1999043345A1 (en) 1998-02-26 1999-09-02 Eisai Co., Ltd. Amino acid degrading enzymes modulate cell death
US6413757B1 (en) * 2000-02-28 2002-07-02 Millennium Pharmaceuticals, Inc. 25312, a novel human agmatinase-like homolog
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
DE10047204A1 (de) 2000-09-23 2002-04-25 Henkel Kgaa Topische Hautbehandlungsmittel mit Arginase
KR20040004449A (ko) 2000-11-28 2004-01-13 휘닉스 파머컬러직스, 인크. 변형된 아르기닌 데이미나제
WO2003063780A2 (en) 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054308A (en) * 1996-03-14 2000-04-25 Smithkline Beecham Corporation Arginase II
US6261557B1 (en) * 1996-08-16 2001-07-17 Slobodan Tepic Arginine decomposing enzyme therapeutic composition
EP0825260A2 (en) * 1996-08-20 1998-02-25 Smithkline Beecham Corporation Arginase II
CN1324942A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶9和编码这种多肽的多核苷酸
CN1324945A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——精氨酸酶12和编码这种多肽的多核苷酸
CN1345966A (zh) * 2000-09-26 2002-04-24 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶35.42和编码这种多肽的多核苷酸
CN1345970A (zh) * 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——含精氨酸酶结构域的蛋白质9.35和编码这种多肽的多核苷酸

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AAA51776.NCBI GENEBANK.1994,1. *
K.V.Savoca等.Cancer Therapy with Chemically ModifiedEnzymes.II.TheTherapeutic Effectiveness of Arginase,andArginase Modifiedby the Covalent Attachment of polyethyleneGlycol,on theTaper Liver Tumor and the L5178Y MurineLeukemia.Cancer Biochem Biophys.7.1984,7261-268. *
Masaki IKEMOTO等.Expression of human liver arginase in EscherichiacoliPurification and properties of the product.Biochem.J.270.1990,270697-703. *
Masaki IKEMOTO等.Expression of human liver arginaseinEscherichiacoliPurification and properties of the product.Biochem.J.270.1990,270697-703. *
姜忠义 等.生物分子化学修饰用聚乙二醇衍生物的合成及应用.高分子通报 1.2002,(1),34-40.
姜忠义等.生物分子化学修饰用聚乙二醇衍生物的合成及应用.高分子通报 1.2002,(1),34-40. *

Also Published As

Publication number Publication date
HK1053577A2 (en) 2003-10-10
DE60331871D1 (de) 2010-05-06
IL165858A0 (en) 2006-01-15
ATE461707T1 (de) 2010-04-15
JP2010148509A (ja) 2010-07-08
US20080248018A1 (en) 2008-10-09
WO2004001048A1 (en) 2003-12-31
IL165858A (en) 2010-12-30
HK1071687A1 (en) 2005-07-29
MXPA04012970A (es) 2005-08-18
EP1517699A1 (en) 2005-03-30
JP5307042B2 (ja) 2013-10-02
AU2002325782A1 (en) 2004-01-06
DE60319083D1 (de) 2008-03-27
US8679810B2 (en) 2014-03-25
US20080226617A1 (en) 2008-09-18
EP1517699B1 (en) 2008-02-13
US20050244398A1 (en) 2005-11-03
ATE385807T1 (de) 2008-03-15
CN1918298A (zh) 2007-02-21
CN101433714A (zh) 2009-05-20
NZ537774A (en) 2007-01-26
US7951366B2 (en) 2011-05-31
DE60319083T2 (de) 2009-02-05
HK1109876A1 (en) 2008-06-27
US20090123450A1 (en) 2009-05-14
JP2013172743A (ja) 2013-09-05

Similar Documents

Publication Publication Date Title
CN1918298B (zh) 利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法
CN101812438B (zh) 一种精氨酸脱亚氨酶突变体及其制备与应用
CN105142663A (zh) 用于癌症靶向治疗的含有结合白蛋白的精氨酸脱亚胺酶的药物组合物
EP1908478B1 (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
JPS62289187A (ja) ヒトマンガンス−パ−オキシドジスムタ−ゼ↓ｃＤＮＡ、その細菌中での発現及び酵素活性ヒトマンガンス−パ−オキシドジスムタ−ゼの回収方法
Van Poelje et al. Cloning, sequencing, expression, and site-directed mutagenesis of the gene from Clostridium perfringens encoding pyruvoyl-dependent histidine decarboxylase
JP2002501032A (ja) 急性間欠性ポルフィリン症（ａｉｐ）及び他のポルフィリン症の治療方法
US10183062B2 (en) Treatment for cancer
WO2023044479A1 (en) Methods for reducing hyperphenylalaninemia
CN114762732A (zh) 控释微球及其抗衰老的用途
TWI331531B (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
JP2003505057A (ja) ｒｈＰＢＧＤの製造及び急性間欠性ポルフィリン症（ＡＩＰ）及び他のポルフィリン症の患者を処置するための新規な治療方法
US20080292609A1 (en) Use of Arginase in Combination with 5FU and Other Compounds for Treatment of Human Malignancies
US5045471A (en) Cloned DNA for P450scc and expression thereof
WO2006058486A1 (en) Use of arginase in combination with 5fu and other compounds for treatment of human malignancies
EP2210611A1 (en) Use of the sequence encoding the carboxyl-terminal domain of the heavy chain of tetanus toxin as a drug
JP2002536015A (ja) ニトロレダクターゼ酵素
KR20050024361A (ko) 아르기닌 결핍에 의한 인간 악성 종양의 치료제 및 치료방법
HK1109876B (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
WO2026067311A1 (zh) 一种工程菌及其构建方法与应用
HK1071687B (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
HK40116920A (zh) Sarm1表达降低用於细胞疗法
CN117586997A (zh) 粘红酵母来源的苯丙氨酸解氨酶突变体及其应用
JPH03161447A (ja) 耐熱性中性プロテアーゼを含む制癌剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20110629